Eli Lilly launched TuneLab, an AI platform granting biotech companies access to predictive models trained on Lilly’s extensive drug discovery data. This federated learning system protects proprietary data while enabling users to improve models collectively. TuneLab initially offers 18 models predicting small-molecule properties and antibody developability, aiming to democratize AI tools for early-stage drug development and foster collaboration in the biotech ecosystem.